renal%20cancer
RENAL CANCER

Renal cancer is the disease in which certain tissues of the kidney starts to grow uncontrollably and form a tumor.

It is also called as renal adenocarcinoma or hypernephroma.

Classic triad of symptoms are flank pain, palpable abdominal mass and gross hematuria.

Principles of Therapy

  • To reduce remission
  • To reduce mortality
  • To prevent complications

Pharmacotherapy

Cancer Immunotherapy

Aldesleukin or Interleukin-2

  • Modified form of interleukin-2 produced by recombinant DNA technology
  • Promotes proliferation, differentiation & recruitment of T & B cells, natural killer (NK) cells & thrombocytes
  • Used for treatment of advanced metastatic renal cell carcinoma (RCC)

Cytotoxic Chemotherapy

Axitinib

  • Second-generation, potent tyrosine kinase inhibitor that selectively targets vascular endothelial growth factors (VEGF) 1, 2 & 3 & inhibits angiogenesis, metastasis & tumor growth
  • Used for treatment of advanced or metastatic RCC after failure of 1 prior systemic therapy

Bevacizumab + Interferon

  • Recombinant humanized monoclonal antibody that binds to VEGF that inhibits angiogenesis occuring during the growth of the tumor
  • Based from the AVOREN (phase III) double-blind trial, the addition of Bevacizumab to Interferon-alfa (IFN-α) significantly increases progression-free survival (PFS)
  • Used for treatment of advanced or metastatic RCC

Everolimus

  • Used for treatment of advanced RCC after treatment failure w/ Sorafenib or Sunitinib
  • The RECORD-1 trial results revealed that Everolimus can be safely given to patients w/ previous intolerance to vascular endothelial growth factor receptors-tyrosine kinase inhibitor (VEGFr-TKI) therapy

Pazopanib

  • An oral angiogenesis inhibitor that targets the VEGFR-1, -2, & -3, platelet-derived growth factor receptors (PDGFR-α & -β) & stem cell factor receptor (c-KIT)
  • Used for treatment of advanced or metastatic RCC
  • It is important to monitor the liver function tests (LFTs) before & during treatment w/ Pazopanib

Sorafenib

  • Small molecule that inhibits multiple isoforms of the intracellular serine/threonine kinase, RAF & also other receptor tyrosine kinases, including VEGFR-1, -2, & -3, PDGFR-β, FMS-like tyrosine kinase (FLT-3), c-KIT & neurotrophic factor receptor (RET)
  • Used for treatment of advanced or metastatic RCC

Sunitinib

  • Multikinase inhibitor targeting several tyrosine kinase inhibitors that is implicated in PDGFR-α & -β, VEGFR-1, -2, & -3, FLT-3, colony-stimulating factor (CSF-1R) & (RET)
  • Used for treatment of advanced or metastatic RCC

Temsirolimus

  • Inhibitor of the mammalian target of rapamycin (mTOR) protein
  • Regulates micronutrients, cell growth, apoptosis & angiogenesis by its downstream effects on a variety of proteins
  • Used for treatment of advanced or metastatic RCC

Other medications that can be used for advanced or metastatic RCC

Cabozantinib

  • According to the results of an interim analysis of the Phase III METEOR trial, it has significantly delayed the progression of the disease as compared w/ Everolimus in patients w/ advanced clear cell renal cell carcinoma (ccRCC) w/ prior VEGR-TKI treatment
  • The trial results showed that Cabozantinib was able to shrink the tumors & slow down the tumor growth
  • Also being studied as a potential first-line treatment & is in early trials combining
  • Cabozantinib w/ immune checkpoint inhibitors
  • Can be used as treatment for advanced or metastatic RCC

Nivolumab

  • A human programmed death receptor-1 (PD-1) blocking antibody used in patients who already received angiogenesis inhibitor therapy
  • Can be used as treatment for advanced or metastatic RCC
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 13 Jan 2020
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
Stephen Padilla, 6 days ago
The Lancet Commission on Hypertension Group has recently released a position statement that contains a list of recommendations for the improvement of accuracy standards for devices that measure blood pressure (BP).